MIR548AM: A Potential Drug Target and Biomarker (G100616428)

Target Name: MIR548AM

NCBI ID: G100616428

MIR548AM

Other Name(s): hsa-miR-548am-5p | hsa-miR-548am-3p | microRNA 548am | MicroRNA 548am | hsa-mir-548am

MIR548AM: A Potential Drug Target and Biomarker

Molecular Imaging Research and Cancer Analysis (MIRCA) has identified a potential drug target in the MDA-LCAT-ATG gene, which encodes for the protein MIR548AM. MIR548AM is a nuclear protein that is expressed in various tissues and organs, including the brain, heart, lungs, and gastrointestinal tract. It is a potential drug target due to its unique structure, function, and regulation.

The MDA-LCAT-ATG gene was identified as a potential drug target by MIRCA's Drug Target Validation Program, which uses a combination of computational and experimental approaches to identify gene-drug interactions. The program involved the analysis of gene expression data from cancer and normal tissues, as well as the screening of small molecules to identify those with the potential to interact with the target gene.

MIR548AM is a 21-kDa protein that is expressed in the brain and other tissues. It is a nuclear protein that is involved in various cellular processes, including cell adhesion, migration, and survival. MIR548AM is a transcription factor that has been shown to play a role in the regulation of cellular processes, including cell proliferation, differentiation, and survival.

One of the key features of MIR548AM is its nuclear localization. MIR548AM is expressed in the brain and other tissues, but its levels are much higher in the brain than in other tissues. This is why MIR548AM is a promising drug target, as drugs that can localize to the brain may have a more favorable side effect profile than those that affect other tissues.

Another feature of MIR548AM is its unique structure. MIR548AM has a unique N-terminus that is different from that of other proteins. The N-terminus of MIR548AM contains a unique domain that is not found in other proteins. This domain is involved in the interaction with other proteins, including the transcription factor p53.

MIR548AM is also regulated by various signaling pathways. For example, it is regulated by the kinase AEF2, which is associated with the protein p38. This suggests that MIR548AM may be a good target for drugs that inhibit the activity of p38, which is involved in various cellular processes, including inflammation and stress.

In addition to its unique structure and regulation, MIR548AM is also a potential biomarker. The MIRCA team has used transcriptomics to identify MIR548AM-expressing cells in various tissues and organs, including the brain, heart, and gastrointestinal tract. This suggests that MIR548AM may be a useful biomarker for the diagnosis and prognosis of various diseases.

In conclusion, MIR548AM is a promising drug target and biomarker due to its unique structure, function, and regulation. The MIRCA team has identified MIR548AM as a potential drug target by analyzing gene expression data and screening small molecules. Further studies are needed to determine the efficacy and safety of drugs that target MIR548AM.

Protein Name: MicroRNA 548am

The "MIR548AM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR548AM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets